[Pharmacotherapy of obesity].
Obesity is a chronic disease with a worldwide increasing incidence. The mainstay of therapy consists in modification of behaviour related to obesity such as overeating and physical inactivity. When these life-style modifying attempts fail, the use of anti-obesity drugs is warranted. The two available drugs, orlistat and sibutramine, are capable of reducing body weight by 10%. Failure of these medications in a subset of patients to achieve adequate weight loss and limited overall efficacy have led to an extensive research on novel anti-obesity agents. This review presents an overview on the current drugs available as well as on potential future candidates.
Tripp
Barbara
B
Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Wien, Osterreich. barbara.tripp@meduniwien.ac.at
Ludvik
Bernhard
B
D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D012528:Satiety Response / Q000187:drug effects; D016896:Treatment Outcome
D001067:Appetite Depressants; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine
Medikamentöse Therapie der Adipositas.